Oxyquinoline

ALIMENTARY TRACT AND METABOLISM

Key facts

Oxyquinoline is an ofp drug catalogued in DrugCentral. DrugCentral lists 7 molecular targets, including Bacterial leucyl aminopeptidase, COMT and METAP2.

• Approval status: ofp.
• Molecular targets: Bacterial leucyl aminopeptidase, COMT, METAP2 and HDAC8 (7 listed in DrugCentral).
• ATC code: A01AB07 (Antiinfectives and antiseptics for local oral treatment).
• Molecular formula: C9H7NO; molecular weight 145.16 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Contraindications (1)

• Sensation Disturbance of Genitals

Mechanism & targets

Molecular targets (7)

Target	Gene	Action	Activity
Bacterial leucyl aminopeptidase	—	unknown	Ki 6.80
Catechol O-methyltransferase	COMT	unknown	IC50 5.80
Methionine aminopeptidase 2	METAP2	unknown	IC50 5.69
Histone deacetylase 8	HDAC8	unknown	EC50 4.96
Catechol O-methyltransferase	Comt	unknown	IC50 4.67
Methionine aminopeptidase 1	METAP1	unknown	IC50 4.67
72 kDa type IV collagenase	MMP2	unknown	IC50 3.89

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
—	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
A01AB07	ALIMENTARY TRACT AND METABOLISM › STOMATOLOGICAL PREPARATIONS › STOMATOLOGICAL PREPARATIONS › Antiinfectives and antiseptics for local oral treatment
D08AH03	DERMATOLOGICALS › ANTISEPTICS AND DISINFECTANTS › ANTISEPTICS AND DISINFECTANTS › Quinoline derivatives
G01AC30	GENITO URINARY SYSTEM AND SEX HORMONES › GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS › ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS › Quinoline derivatives
R02AA14	RESPIRATORY SYSTEM › THROAT PREPARATIONS › THROAT PREPARATIONS › Antiseptics

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Apparent death	226.7
Intestinal sepsis	141.7
Diverticulitis	108.6
Pulmonary thrombosis	107.0
Terminal state	103.4
Photosensitivity reaction	99.1
Red blood cell sedimentation rate increased	94.0
Joint arthroplasty	81.8
C-reactive protein increased	76.5
Deep vein thrombosis	66.5
Pulmonary embolism	63.8
C-reactive protein abnormal	59.3

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Oxyquinoline is on its molecule page.

• Molecular formula: C₉H₇NO
• Molecular weight: 145.16 g/mol
• CAS number: —
• InChIKey: MCJGNVYPOGVAJF-UHFFFAOYSA-N
• PubChem CID: 1923

OC1=CC=CC2=C1N=CC=C2

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

How does Oxyquinoline work?

Its molecular targets in DrugCentral include Bacterial leucyl aminopeptidase, COMT, METAP2 and HDAC8.

What is the chemical formula of Oxyquinoline?

Oxyquinoline has the molecular formula C9H7NO and a molecular weight of 145.16 g/mol.

Sources

• DrugCentral drug card 3290 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1697698 — compound record and bioactivity
• PubChem CID 1923 — chemical identifiers
• DrugBank DB11145 — drug record
• FDA UNII 5UTX5635HP — substance identity
• DailyMed: FDA labels for Oxyquinoline — current prescribing information (label search)
• UniProt P21964 (COMT) — target protein
• UniProt P50579 (METAP2) — target protein
• UniProt Q9BY41 (HDAC8) — target protein
• UniProt P53582 (METAP1) — target protein
• UniProt P08253 (MMP2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.